Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;29(2):217-30.
doi: 10.1080/10550881003684814.

Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine

Annemarie Unger  1 , Erika Jung, Bernadette Winklbaur, Gabriele Fischer
Affiliations

Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine

Annemarie Unger et al. J Addict Dis. 2010 Apr.

Abstract

Gender, a biological determinant of mental health and illness, plays a critical role in determining patients' susceptibility, exposure to mental health risks, and related outcomes. Regarding sex differences in the epidemiology of opioid dependence, one third of the patients are women of childbearing age. Women have an earlier age of initiation of substance use and a more rapid progression to drug involvement and dependence than men. Generally few studies exist which focus on the special needs of women in opioid maintenance therapy. The aim of this paper is to provide an overview of treatment options for opioid-dependent women, with a special focus on buprenorphine, and to look at recent findings related to other factors that should be taken into consideration in optimizing the treatment of opioid-dependent women. Issues addressed include the role of gender in the choice of medication assisted treatment, sex differences in pharmacodynamics and pharmacokinetics of buprenorphine drug interactions, cardiac interactions, induction of buprenorphine in pregnant patients, the neonatal abstinence syndrome and breastfeeding. This paper aims to heighten the awareness for the need to take gender into consideration when making treatment decisions in an effort to optimize services and enhance the quality of life of women suffering from substance abuse.

Keywords: Gender; buprenorphine; neonatal abstinence syndrome; opioid dependence.

PubMed Disclaimer

References

    1. World Health Organization. Department of Mental Health and Substance Dependence. Gender Disparities in Mental Health. 2002. [accessed 18/03/2008]. available at: www.who.int/mental_health/media/en/242.pdf.
    1. National Survey on Drug Use and Health. Gender differences in substance dependence and abuse. SAMHSA. 2003. [accessed 20/03/2008]. Available at http://oas.samhsa.gov/2k4/genderDependence/genderDependence.htm.
    1. Fischer G, Eder H. Interdisciplinary therapeutic approaches with substance abusers taking into consideration gender differences. Wien Med Wochensch. 1999;149(11):331–336. - PubMed
    1. Zilberman M, Tavares H, el-Guebaly N. Gender similarities and differences: the prevalence and course of alcohol- and other substance-related disorders. Journal of Addictive Diseases. 2003;22(4):61–74. - PubMed
    1. Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, Sargent PL. Incidence and risk factors for hepatitis C seroconvulsion in injection drug users in Australia. Addiction. 2006;10:1499–1508. - PubMed

Publication types